Ibuprofen as a pre-emptive analgesic is as effective as rofecoxib for mandibular third molar surgery

Odontology

Volumn 94, Issue 1, 2006, Pages 59-63

  Morse, Zac ^a   Tump, Anna ^b   Kevelham, Ester ^b  

^a FIJI SCHOOL OF MEDICINE   (Fiji)

^b UNIVERSITY OF GRONINGEN   (Netherlands)

Author keywords

Dental pain; Ibuprofen; Post operative dental pain; Pre emptive analgesia; Rofecoxib; Third molar surgery

Indexed keywords

CYCLOOXYGENASE 2 INHIBITOR; IBUPROFEN; LACTONE; NONSTEROID ANTIINFLAMMATORY AGENT; ROFECOXIB; SULFONE;

ADOLESCENT; ADULT; AGED; ANALYSIS OF VARIANCE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; MALE; MIDDLE AGED; MOLAR TOOTH; MULTICENTER STUDY; NONPARAMETRIC TEST; PAIN ASSESSMENT; POSTOPERATIVE PAIN; PREMEDICATION; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; TOOTH EXTRACTION;

ADOLESCENT; ADULT; AGED; ANALYSIS OF VARIANCE; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CYCLOOXYGENASE 2 INHIBITORS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; IBUPROFEN; LACTONES; MALE; MIDDLE AGED; MOLAR, THIRD; PAIN MEASUREMENT; PAIN, POSTOPERATIVE; PREMEDICATION; PROSPECTIVE STUDIES; STATISTICS, NONPARAMETRIC; SULFONES; TOOTH EXTRACTION;

EID: 33749074481     PISSN: 16181247     EISSN: 16181255     Source Type: Journal    
DOI: 10.1007/s10266-006-0062-4     Document Type: Article

References (27)

1. F Berenbaum 2003 Non-steriodal anti-inflammatory agents Rev Prat 53 502-6 12722607
2. MK Urban 2000 Cox-2 specific inhibitors offer improved advantages over traditional NSAIDs Orthopedics 23 761-4
3. JR Vane 1971 Inhibition of prostaglandin synthesis as a mechanism of action of aspirin-like drugs Nat New Biol 231 232-5 5284360
4. DJ Bjorkman 1998 The effect of aspirin and nonsteroidal anti-inflammatory drugs on prostaglandins Am J Med 105 8S-12S 9715829 10.1016/S0002-9343(98)00069-2
5. LJ Scott HM Lamb 1999 Rofecoxib Drugs 58 499-505 10493277 10.2165/ 00003495-199958030-00016
6. J Cashman G McAnulty 1995 Nonsteriodal anti-inflammatory drugs in perisurgical pain management. Mechanism of action and rationale for optimum use Drugs 49 51-70 7705216
7. EW Ehrich A Dallob A Lepeleire 1999 Characterization of rofecoxib as a cyclooxygenase-2 isoform inhibitor and demonstration of analgesia in the dental pain model Clin Pharmacol Ther 65 336-47 10096266 10.1016/ S0009-9236(99)70113-X
8. TJ Smith 1998 Cyclooxygenases as the principal targets for the action of NSAIDs Rheum Dis Clin North Am 24 501-23 9710884 10.1016/ S0889-857X(05)70023-5
9. L Pronai I Hritz B Molnar L Herszenyi Z Tulassay 2003 COX-2-selective inhibitors (COXIBs): Gastrointestinal safety Int J Immunopathol Pharmacol 16 23-30 14552701
10. S Tacconelli MG Sciulli P Patrignani 2003 Clinical pharmacology of selective COX-2 inhibitors Int J Immunopathol Pharmacol 16 49-58 14552704
11. L Laine 2002 The gastrointestinal effects of nonselective NSAIDs and COX-2-selective inhibitors Semin Arthritis Rheum 32 25-32 12528071 10.1053/sarh.2002.37217
12. DA Peura 2002 Gastrointestinal safety and tolerability of nonselective nonsteroidal anti-inflammatory agents and cyclooxygenase-2-selective inhibitors Cleve Clin J Med 69 131-9
13. MJ Langman J Weil P Wainwright 1994 Risk of bleeding peptic ulcer associated with individual non-steriodal anti-inflammatory drugs Lancet 343 1075-8 7909103 10.1016/S0140-6736(94)90185-6
14. RA Seymour JM Simpson JE Charlton ME Phillips 1985 An evaluation of length and end-phrase of visual analogue scales in dental pain Pain 21 177-85 3982841 10.1016/0304-3959(85)90287-8
15. K Sriwatanakul W Kelvie L Lasagna JF Alimlim OF Weis G Mehta 1983 Studies with different types of visual analog scales for measurement of pain Clin Pharmacol Ther 34 234-9 6872418
16. http://www.nps.org.au/resources/content/nps_factsheet_vioxx_20041001.pdf Updated 7 October 2004
17. MR Griffin CM Stein JR Daugherty DJ Graham PG Arbogast WA Ray 2004 High frequency of use of rofecoxib at greater than recommended doses: Cause for concern Pharmacoepidemiol Drug Saf 13 339-43 15170762 10.1002/pds.879
18. BW Morrison J Fricke J Brown W Yuan P Kotey D Mehlisch 2000 The optimal analgesic dose of rofecoxib: Overview of six randomized controlled trails J Am Dent Assoc 131 1729-37 11143737
19. http://www.nps.org.au/site.php?content=/html/news.php&news=/ resources/NPS_News/news18
20. GG Graham KF Scott 2003 Mechanism of action of paracetamol and related analgesics Inflammopharmacology 11 401-13 15035793 10.1163/ 156856003322699573
21. DA Willoughby AR Moore PR Colville-Nash 2000 COX-1, COX-2, and COX-3 and the future treatment of chronic inflammatory disease Lancet 355 646-8 10696997 10.1016/S0140-6736(99)12031-2
22. SS Ayoub RM Botting S Goorha PR Colville-Nash DA Willoughby LR Ballou 2004 Acetaminophen-induced hypothermia in mice is mediated by a prostaglandin endoperoxide synthase 1 gene-derived protein Proc Natl Acad Sci USA 19 11165-9 10.1073/pnas.0404185101
23. AH Jeske 2002 Selecting new drugs for pain control: Evidence-based decisions or clinical impressions? J Am Dent Assoc 133 1052-6 12198983
24. AJ Matheson DP Figgit 2001 Rofecoxib: A review of its use in the management of osteoarthritis, acute pain and rheumatoid arthritis Drugs 61 833-65 11398914 10.2165/00003495-200161060-00019
25. AH Jeske 1999 COX-2 inhibitor and dental pain control J Gt Houst Dent Soc 71 39-40 10825891
26. K Malstrom S Daniels P Kotey BC Seidenberg PJ Desjardins 1999 Comparison of rofecoxib and celecoxib, two cyclooxyenase-2 inhibitors, in postoperative dental pain: A randomized, placebo-, and active-comparator-controlled clinical trial Clin Ther 21 1653-63 10.1016/ S0149-2918(99)80045-9
27. BW Morrison S Christensen W Yuan J Brown S Amlani B Seidenberg 1999 Analgesic efficacy of the cyclooxigenase-2-specific inhibitor rofecoxib in post-dental surgery pain: A randomized, controlled trial Clin Ther 21 943-53 10440619 10.1016/S0149-2918(99)80016-2